Evidence map›Paper›PMID 35385150›Full record

Observational studyMuscle & nerve2022

Distribution of weight, stature, and growth status in children and adolescents with spinal muscular atrophy: An observational retrospective study in the United States.

Basil T Darras, Sabrina Guye, Janine Hoffart, Sophie Schneider, Isaac Gravestock, Ksenija Gorni, Sabine Fuerst-Recktenwald, Renata S Scalco, Richard S Finkel, Darryl C De Vivo

Abstract readObservational Study
In one paragraph

Observational study in Muscle & nerve, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Basil T DarrasDepartment of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-1536-8145
Sabrina GuyeF. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID 0000-0003-0864-9296
Janine HoffartF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Sophie SchneiderF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Isaac GravestockF. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID 0000-0003-0283-2065
Ksenija GorniPDMA, Neuroscience and Rare Disease, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Sabine Fuerst-RecktenwaldF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Renata S ScalcoPharma Development Neurology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Richard S FinkelCenter for Experimental Neurotherapeutics, St Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID 0000-0002-9351-7054
Darryl C De VivoDepartments of Neurology and Pediatrics, Columbia University Irving Medical Center, New York, New York, USA.ORCID 0000-0001-8420-0795

Funding

F. Hoffmann-La Roche Ltd
6 · The paper itself

Abstract

INTRODUCTION/

aimsData regarding weight, height/length, and growth status of patients with spinal muscular atrophy (SMA) who have received only supportive care are limited. This cross-sectional study describes these measurements in patients with Type 1 and Types 2/3 SMA and compares them with reference values from typically developing children.

methodsRetrospective baseline data from three sites in the Pediatric Neuromuscular Clinical Research Network (Boston, New York, Philadelphia) were used. Descriptive statistics for weight, height/length, body mass index-for-age, as well as weight-for-length and absolute and relative deviations from reference values (ie, 50th percentile from World Health Organization/Centers for Disease Control growth charts) were calculated. Furthermore, growth status was reported.

resultsA total of 91 genetically confirmed patients with SMA receiving optimal supportive care and without any disease-modifying treatment were stratified into Types 1 (n = 28) and 2/3 SMA (n = 63). Patients with Type 1 SMA weighed significantly less (median = -7.5%) compared with reference values and patients with Types 2/3 SMA were significantly shorter (mean = -3.0%) compared with reference values. The median weight was considerably below the 50th percentile in both groups of patients, even if they received a high standard of care and proactive feeding support. DISCUSSION: More research is needed to understand which factors influence growth longitudinally, and how to accurately capture growth in patients with SMA. Further research should investigate the best time to provide feeding support to avoid underweight, especially in patients with Type 1, and how to avoid the risk of overfeeding, especially in patients with Types 2/3 SMA.

Indexed as

Muscular Atrophy, SpinalSpinal Muscular Atrophies of ChildhoodAdolescentBody HeightChildCross-Sectional StudiesHumansRetrospective StudiesUnited Statesbody mass indexgrowth statusheightobesityspinal muscular atrophyweight

Identifiers

PMID35385150
PMCPMC9325433

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.